Can this man bring down the cost of some of the most expensive and hope-inspiring new therapies on the market?
I recently had the pleasure of sitting down with Fabian Gerlinghaus, CEO of Cellares. They are working on closed-system full automation to manufacture cell therapies.
This was at JPM Week 2025 in San Francisco.
I hope you enjoy watching!
Yours sincerely,
Dr. Adil Ali
Lexicon's latest drug for obesity and weight management has a novel mechanism and is backed by Novo Nordisk.
FLIM LABS is redesigning the tools of fluorescence-lifetime imaging to enable broader access across medicine, pharma, and environmental science.
Allucent are helping small- to mid-sized biotechs stay nimble.
Ever thought a probiotic could help manage blood sugar by stimulating GLP-1?
